Lisa Miller Wruck, PhD
|Clinical Associate Professor
|Collaborative Studies Coordinating Center
137 E. Franklin St.
Campus Box 8030
Chapel Hill, NC 27514
|2004||Harvard University||PhD, Biostatistics|
|1997||Tulane University||MSPH, Biostatistics|
|1993||University of Florida||BS, Mathematics|
- Clinical Trials
- Cardiovascular epidemiology
- Analysis of administrative claims data (especially CMS)
As a co-PI of the Atherosclerosis Risk in Communities (ARIC) Coordinating Center and a PI of the ARIC Neurocognitive Study (NCS) Coordinating Center, I am responsible for providing statistical input on issues related to study operations. I am deeply involved in ARIC Community Surveillance operations, oversee Coordinating Center operations on dementia endpoint classification for NCS and I manage processing and linking of Medicare (CMS) data with ARIC cohort data.
I direct analyses for manuscripts based on ARIC, ARIC NCS and ARIC CMS data, collaborating with subject matter experts on analyses of mid-life vascular risk factors for dementia and cognitive decline in the elderly as well as manuscripts based on ARIC cohort and community surveillance of MI, CHD deaths, heart failure and stroke.
I have worked as a coordinating center biostatistician, investigator and PI for several large NIH-funded multi-center clinical trial networks, including Pediatric Heart Network, Urinary Incontinence Treatment Network, Sickle Cell Disease Clinical Research Network, Comprehensive Sickle Cell Centers, Autoimmune Disease Clinical Trials network and the Atopic Dermatitis Research Network. I am currently involved in planning of the ACHIEVE Healthy Aging Clinical Trial, in which we will assess the impact of an auditory intervention on cognitive decline in older adults with hearing loss.
Gottesman RF, Schneider AL, Albert M, Alonso A, Bandeen-Roche K, Coker LH, Coresh J, Knopman D, Power MC, Rawlings AM, Sharrett AR, Wruck L, Mosley TH. Midlife hypertension and 20-year cognitive change: The Atherosclerosis Risk in Communities (ARIC) Neurocognitive Study. JAMA Neurol. 2014 Aug 4. PubMed PMID: 25090106.
Chang PP, Chambless LE, Shahar E, Bertoni AG, Russell SD, Ni H, He M, Mosley TH, Wagenknecht LE, Samdarshi TE, Wruck LM, Rosamond WD. Incidence and Survival of Hospitalized Acute Decompensated Heart Failure in Four US Communities (from the Atherosclerosis Risk in Communities Study). Am J Cardiol. 2013 Nov 9. pii: S0002-9149(13)02162-0.
Pocock SJ, Travison TG, Wruck LM. How to interpret figures in reports of clinical trials. BMJ. 2008 May 24;336(7654):1166-9.
Lacro RV, Dietz HC, Wruck LM, Bradley TJ, Colan SD, Devereux RB, Klein GL, Li JS, Minich LL, Paridon SM, Pearson GD, Printz BF, Pyeritz RE, Radojewski E, Roman MJ, Saul JP, Stylianou MP, Mahony L; Pediatric Heart Network Investigators. Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome. Am Heart J. 2007 Oct;154(4):624-31.
Wruck LM, Yiannoutsos CT, Hughes MD. A sequential design to estimate sensitivity and specificity of a diagnostic or screening test. Stat Med. 2006 Oct 30;25(20):3458-73.